🔴 Moleculin Biotech is trading 5.5% down today amid biotech-sector weakness

Moleculin Biotech is trading at $0.45, down 5.52%, with biotech-sector weakness a possible contributing factor.

• No clear company-specific catalyst was identified for the October 6 decline.
• The latest reported clinical-trial update was September 29; an October 5 corporate presentation was listed without evidence of a new material development.
• Biotech ETF XBI was down 2.50%, supporting sector weakness as a contributing explanation but not establishing the cause of Moleculin Biotech’s move.